Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
Accenture
Mallinckrodt
Cipla
McKinsey
Colorcon

Generated: September 15, 2019

DrugPatentWatch Database Preview

Details for Patent: 9,227,946

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,227,946
Title:1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1a activity for the treatment of cognitive impairment
Abstract: 1-[2-(2,4-dimethylphenylsulphanyl)phenyl]piperazine exhibits potent activity on SERT, 5-HT.sub.3 and 5-HT.sub.1A and may as such be useful for the treatment of cognitive impairment, especially in depressed patients.
Inventor(s): Faldt; Andre (Ishoj, DK), Holm; Rene (Jyllinge, DK), de Diego; Heidi Lopez (Naerum, DK)
Assignee: H. Lundbeck A/S (Copenhagen-Valby, DK)
Application Number:14/242,337
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,227,946
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 9,227,946

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Takeda Pharms Usa TRINTELLIX vortioxetine hydrobromide TABLET;ORAL 204447-001 Sep 30, 2013 RX Yes No ➤ Sign Up ➤ Sign Up METHOD OF TREATING DEPRESSION OR MAJOR DEPRESSIVE DISORDER ➤ Sign Up
Takeda Pharms Usa TRINTELLIX vortioxetine hydrobromide TABLET;ORAL 204447-002 Sep 30, 2013 RX Yes No ➤ Sign Up ➤ Sign Up METHOD OF TREATING DEPRESSION OR MAJOR DEPRESSIVE DISORDER ➤ Sign Up
Takeda Pharms Usa TRINTELLIX vortioxetine hydrobromide TABLET;ORAL 204447-003 Sep 30, 2013 DISCN Yes No ➤ Sign Up ➤ Sign Up METHOD OF TREATING DEPRESSION OR MAJOR DEPRESSIVE DISORDER ➤ Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Subscribe to access the full database, or try a Free Trial

Foreign Priority and PCT Information for Patent: 9,227,946

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Denmark200600824Jun 16, 2006
Denmark200601223Sep 22, 2006
Denmark200601384Oct 25, 2006

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Teva
Johnson and Johnson
US Department of Justice
Medtronic
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.